The percentage of CD4+CXCR5+ cTfh cells was lower in 12 months DMF-treated compared to untreated RRMS patients (7.7 vs. 11.4%; p < 0.01) (Figure 5A, upper panel). This evidence concerns the gene CXCR5 and relapsing-remitting multiple sclerosis.